{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:23:57Z","timestamp":1793816637408,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017653","name":"Fonds Sp\u00e9ciaux de Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to identify the most frequently reported outcomes in sarcopenia trials, as a basis for developing a Core Outcome Set (COS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>A systematic review was conducted with a comprehensive search of MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from database inception to March 2024 (PRISMA guidelines, PROSPERO: CRD42024525506). Eligible studies were randomized controlled trials (RCTs) on sarcopenia treatment, including patients diagnosed with a consensus definition. All outcomes reported in those studies were extracted and grouped into predefined subcategories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3985 references, 58 studies (54 unique RCTs) met the inclusion criteria, reporting 214 efficacy and 39 safety outcomes. The most frequently reported outcomes were muscle mass (50 studies, i.e., present in 86.2% of studies), muscle strength (50 studies, 86.2%), physical performance (46 studies, 79.3%), nutrition-related outcomes (29 studies, 50.0%), and fat mass (28 studies, 48.3%). Among the primary outcomes, change in muscle mass was the most commonly reported outcome (23 studies, 39.7%, with appendicular skeletal muscle mass index and fat-free mass as the predominant measures), followed by change in muscle strength (16 studies, 27.6%, mainly assessed by handgrip strength), followed by change in physical performance (13 studies, 22.4%, mainly assessed by gait speed and lower limb physical function). Secondary outcomes included biomarkers, physical status, quality of life, activities of daily living, bone mass, psychological status, cognitive function, and unclassified outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review highlights the extensive heterogeneity of reported outcomes in sarcopenia intervention studies and the urgent need for developing a COS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s41999-025-01285-x","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:28:19Z","timestamp":1755016099000},"page":"2033-2045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Towards a core outcome set for sarcopenia intervention studies: a scoping review identifying the most frequently reported outcomes across randomized controlled trials in sarcopenia"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6705-3672","authenticated-orcid":false,"given":"S.","family":"Van Heden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Baoubbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Surquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sanchez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"1","key":"1285_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16\u201331","journal-title":"Age Ageing"},{"issue":"1","key":"1285_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40520-024-02798-4","volume":"36","author":"B Kirk","year":"2024","unstructured":"Kirk B et al (2024) An executive summary on the Global conceptual definition of Sarcopenia. Aging Clin Exp Res 36(1):153","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"1285_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jcsm.12147","volume":"7","author":"SD Anker","year":"2016","unstructured":"Anker SD, Morley JE, von Haehling S (2016) Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 7(5):512\u2013514","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"8","key":"1285_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jamda.2016.06.001","volume":"17","author":"L Cao","year":"2016","unstructured":"Cao L, Morley JE (2016) Sarcopenia is recognized as an independent condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) code. J Am Med Dir Assoc 17(8):675\u2013677","journal-title":"J Am Med Dir Assoc"},{"key":"1285_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae052","author":"B Kirk","year":"2024","unstructured":"Kirk B et al (2024) The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afae052","journal-title":"Age Ageing"},{"issue":"1","key":"1285_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jcsm.12783","volume":"13","author":"F Petermann-Rocha","year":"2022","unstructured":"Petermann-Rocha F et al (2022) Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 13(1):86\u201399","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1285_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155533","volume":"144","author":"S Yuan","year":"2023","unstructured":"Yuan S, Larsson SC (2023) Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism 144:155533","journal-title":"Metabolism"},{"key":"1285_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40200-017-0302-x","volume":"16","author":"G Shafiee","year":"2017","unstructured":"Shafiee G et al (2017) Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord 16:21","journal-title":"J Diabetes Metab Disord"},{"issue":"3","key":"1285_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00223-016-0220-9","volume":"100","author":"O Ethgen","year":"2017","unstructured":"Ethgen O et al (2017) The future prevalence of sarcopenia in Europe: a claim for public health action. Calcif Tissue Int 100(3):229\u2013234","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"1285_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169548","volume":"12","author":"C Beaudart","year":"2017","unstructured":"Beaudart C et al (2017) Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS ONE 12(1):e0169548","journal-title":"PLoS ONE"},{"issue":"3","key":"1285_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/jcsm.13243","volume":"14","author":"C Beaudart","year":"2023","unstructured":"Beaudart C et al (2023) Sarcopenia and health-related quality of life: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 14(3):1228\u20131243","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1285_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40520-024-02870-z","volume":"36","author":"S Martini","year":"2024","unstructured":"Martini S et al (2024) Validation of the German version of the SarQoL((R)) questionnaire in sarcopenic and probable sarcopenic patients. Aging Clin Exp Res 36(1):217","journal-title":"Aging Clin Exp Res"},{"key":"1285_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.maturitas.2018.11.003","volume":"119","author":"O Bruyere","year":"2019","unstructured":"Bruyere O et al (2019) The health economics burden of sarcopenia: a systematic review. Maturitas 119:61\u201369","journal-title":"Maturitas"},{"issue":"3","key":"1285_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/jcsm.13225","volume":"14","author":"Y Shen","year":"2023","unstructured":"Shen Y et al (2023) Exercise for sarcopenia in older people: a systematic review and network meta-analysis. J Cachexia Sarcopenia Muscle 14(3):1199\u20131211","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"18","key":"1285_CR15","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e146","volume":"37","author":"MR Cho","year":"2022","unstructured":"Cho MR, Lee S, Song SK (2022) A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. J Korean Med Sci 37(18):e146","journal-title":"J Korean Med Sci"},{"issue":"1","key":"1285_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s40520-024-02920-6","volume":"37","author":"Z Fu","year":"2025","unstructured":"Fu Z et al (2025) Seeking optimal non-pharmacological interventions for sarcopenia: a systematic review and network meta-analysis. Aging Clin Exp Res 37(1):24","journal-title":"Aging Clin Exp Res"},{"key":"1285_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155597","volume":"149","author":"Y Rolland","year":"2023","unstructured":"Rolland Y et al (2023) Current and investigational medications for the treatment of sarcopenia. Metabolism 149:155597","journal-title":"Metabolism"},{"issue":"1","key":"1285_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40520-024-02825-4","volume":"36","author":"M Kanbay","year":"2024","unstructured":"Kanbay M et al (2024) Effect of bimagrumab on body composition: a systematic review and meta-analysis. Aging Clin Exp Res 36(1):185","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"1285_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.14283\/jfa.2024.47","volume":"13","author":"GL Doza","year":"2024","unstructured":"Doza GL et al (2024) Impact of interventions on sarcopenia from the perspective of older persons: a systematic literature review. J Frailty Aging 13(3):224\u2013232","journal-title":"J Frailty Aging"},{"issue":"Suppl 3","key":"1285_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR et al (2017) The COMET handbook: version 1.0. Trials 18(Suppl 3):280","journal-title":"Trials"},{"key":"1285_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Bmj"},{"issue":"11","key":"1285_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002447","volume":"14","author":"JJ Kirkham","year":"2017","unstructured":"Kirkham JJ et al (2017) Core outcome set-STAndards for development: the COS-STAD recommendations. PLoS Med 14(11):e1002447","journal-title":"PLoS Med"},{"issue":"1","key":"1285_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13063-019-3230-x","volume":"20","author":"JJ Kirkham","year":"2019","unstructured":"Kirkham JJ et al (2019) Core outcome set-STandardised protocol items: the COS-STAP statement. Trials 20(1):116","journal-title":"Trials"},{"issue":"10","key":"1285_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002148","volume":"13","author":"JJ Kirkham","year":"2016","unstructured":"Kirkham JJ et al (2016) Core outcome set-STAndards for reporting: the COS-STAR statement. PLoS Med 13(10):e1002148","journal-title":"PLoS Med"},{"key":"1285_CR25","doi-asserted-by":"crossref","unstructured":"al., A.M.e., 2012 The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care,. 28:138\u2013144.","DOI":"10.1017\/S0266462312000086"},{"key":"1285_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.12.020","volume":"96","author":"S Dodd","year":"2018","unstructured":"Dodd S et al (2018) A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol 96:84\u201392","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1285_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s41999-022-00706-5","volume":"13","author":"PM Cawthon","year":"2022","unstructured":"Cawthon PM et al (2022) Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee. Eur Geriatr Med 13(6):1239\u20131244","journal-title":"Eur Geriatr Med"},{"issue":"3","key":"1285_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","volume":"21","author":"LK Chen","year":"2020","unstructured":"Chen LK et al (2020) Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 21(3):300-307 e2","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"1285_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s12603-022-1853-1","volume":"26","author":"H Mori","year":"2022","unstructured":"Mori H, Tokuda Y (2022) De-training effects following leucine-enriched whey protein supplementation and resistance training in older adults with sarcopenia: a randomized controlled trial with 24 weeks of follow-up. J Nutr Health Aging 26(11):994\u20131002","journal-title":"J Nutr Health Aging"},{"key":"1285_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/foods10112581","author":"FY Chiang","year":"2021","unstructured":"Chiang FY et al (2021) Effects of milk or soy milk combined with mild resistance exercise on the muscle mass and muscle strength in very old nursing home residents with sarcopenia. Foods. https:\/\/doi.org\/10.3390\/foods10112581"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.exger.2018.09.015","volume":"112","author":"HT Chen","year":"2018","unstructured":"Chen HT et al (2018) Effects of 8-week kettlebell training on body composition, muscle strength, pulmonary function, and chronic low-grade inflammation in elderly women with sarcopenia. Exp Gerontol 112:112\u2013118","journal-title":"Exp Gerontol"},{"issue":"10","key":"1285_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13346","volume":"2","author":"Y Lu","year":"2019","unstructured":"Lu Y et al (2019) Assessment of sarcopenia among community-dwelling at-risk frail adults aged 65 years and older who received multidomain lifestyle interventions: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2(10):e1913346","journal-title":"JAMA Netw Open"},{"key":"1285_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068788","volume":"377","author":"R Bernabei","year":"2022","unstructured":"Bernabei R et al (2022) Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ 377:e068788","journal-title":"BMJ"},{"key":"1285_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214566","author":"M Rondanelli","year":"2022","unstructured":"Rondanelli M et al (2022) Effectiveness of a novel food composed of leucine, omega-3 fatty acids and probiotic Lactobacillus paracasei PS23 for the treatment of sarcopenia in elderly subjects: a 2-month randomized double-blind placebo-controlled trial. Nutrients. https:\/\/doi.org\/10.3390\/nu14214566","journal-title":"Nutrients"},{"issue":"1","key":"1285_CR35","doi-asserted-by":"publisher","first-page":"18756","DOI":"10.1038\/s41598-020-75872-2","volume":"10","author":"Y Liang","year":"2020","unstructured":"Liang Y et al (2020) A randomized controlled trial of resistance and balance exercise for sarcopenic patients aged 80\u201399 years. Sci Rep 10(1):18756","journal-title":"Sci Rep"},{"issue":"6","key":"1285_CR36","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/jcsm.12532","volume":"11","author":"M Rondanelli","year":"2020","unstructured":"Rondanelli M et al (2020) Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. J Cachexia Sarcopenia Muscle 11(6):1535\u20131547","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"1285_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.gerinurse.2015.11.001","volume":"37","author":"BH Hassan","year":"2016","unstructured":"Hassan BH et al (2016) Impact of resistance training on sarcopenia in nursing care facilities: a pilot study. Geriatr Nurs 37(2):116\u2013121","journal-title":"Geriatr Nurs"},{"key":"1285_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.936314","volume":"9","author":"ZR Li","year":"2022","unstructured":"Li ZR et al (2022) Ditangquan exercises based on safe-landing strategies prevent falls and injury among older individuals with sarcopenia. Front Med (Lausanne) 9:936314","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1285_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s40520-020-01663-4","volume":"33","author":"JY Reginster","year":"2021","unstructured":"Reginster JY et al (2021) Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clin Exp Res 33(1):3\u201317","journal-title":"Aging Clin Exp Res"},{"issue":"27","key":"1285_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034254","volume":"102","author":"Q Geng","year":"2023","unstructured":"Geng Q et al (2023) The efficacy of different interventions in the treatment of sarcopenia in middle-aged and elderly people: a network meta-analysis. Medicine (Baltimore) 102(27):e34254","journal-title":"Medicine (Baltimore)"},{"key":"1285_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102014","volume":"90","author":"PT Tseng","year":"2023","unstructured":"Tseng PT et al (2023) Omega-3 polyunsaturated fatty acids in sarcopenia management: a network meta-analysis of randomized controlled trials. Ageing Res Rev 90:102014","journal-title":"Ageing Res Rev"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-025-01285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-025-01285-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-025-01285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:28:38Z","timestamp":1766809718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-025-01285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s41999-025-01285-x","relation":{"references":[{"id-type":"doi","id":"10.3390\/foods10112581","asserted-by":"subject"}]},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a scoping review, for this study type, Ethics Committee approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}